Light and Sound Therapy Offers New Hope for Alzheimer's Patients

Over 7 million Americans aged 65 and older currently live with Alzheimer's disease—a number expected to nearly double by 2060. Worldwide, dementia affects more than 57 million people, with Alzheimer's being the most common form. Now, a new non-invasive approach using light and sound could offer hope for slowing cognitive decline in patients.

Annabelle Singer, an associate professor and biomedical engineer at Georgia Institute of Technology and Emory University, is leading research into a novel brain stimulation method. Her work focuses on patterns of neural activity in Alzheimer's patients, taking a different path from traditional drug-based treatments.

Singer's interest in light and sound began with her background in theatre. This inspiration led her to explore how flickering lights and rhythmic sound at 40 Hz, applied for an hour daily, might help. Early tests suggested this approach could slow cognitive decline and reduce brain volume loss in Alzheimer's patients.

A Phase 3 double-blind clinical trial is now underway, involving nearly 700 participants. Unlike pharmaceutical companies that target molecular-level changes, Singer's method avoids invasive procedures. Recent FDA-approved Alzheimer's drugs, such as lecanemab and donanemab, have shown limited benefits while carrying risks and high costs. Future treatments may combine medicines with alternative therapies like Singer's.

The ongoing trial will determine whether Singer's non-invasive stimulation can become a viable option for Alzheimer's patients. If successful, it could provide a low-risk, drug-free approach to managing cognitive decline. The results may also influence how future treatments integrate different methods to combat the disease.